Rosenberg et al¹ recently reported the outcomes of a phase II, single-arm, multicenter trial assessing efficacy and toxicity of enfortumab vedotin (EV) in patients who had progressed to a median of 3 lines of treatment. Results of this novel therapy in a heavily treated population are encouraging. We congratulate the authors for proceeding with a phase III trial to confirm their findings.

中文翻译：

---

生物标志物表达对于随机临床试验设计的价值：错过了一个（更多）机会。

Rosenberg等[ ^1]最近报告了一项II期，单臂，多中心试验的结果，该试验评估了enfortumab vedotin（EV）对进展为中位三线治疗的患者的疗效和毒性。在受到高度治疗的人群中，这种新颖疗法的结果令人鼓舞。我们祝贺作者进行了III期试验以证实他们的发现。